drugset / Trial / NCT05281549

Thrombolysis Treated With TNK-tPA in Acute Ischemic Stroke Patients (3T Stroke-II)

NCT05281549

RandomizedParallel-groupSingle-blindTreatment

Summary

The trial is prospective, block randomized, open-label, blinded endpoint (PROBE) design. Patients with acute ischemic stroke, who are eligible for standard intravenous thrombolysis within 4.5 hours of stroke onset will be randomized 1:1:1 to 0.25mg/kg or 0.40mg/kg intravenous tenecteplase or 0.9 mg/kg alteplase before all participants undergo endovascular thrombectomy.

Timeline

Start
2021-05-02
Primary completion
2022-01-28
Completion
2022-05-31

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Alteplase Protein / enzyme biologic 0.9 mg/kg Intravenous
Subject Tenecteplase Protein / enzyme biologic 0.25 mg/kg Intravenous
Subject Tenecteplase Protein / enzyme biologic 0.4 mg/kg Intravenous

Indications